轉染技術市場規模、佔有率及成長分析（依方法、應用、最終用戶及地區分類）－2026-2033年產業預測

預計到 2024 年，轉染技術市場規模將達到 13.1 億美元，到 2025 年將達到 14.4 億美元，到 2033 年將達到 29.5 億美元，在預測期（2026-2033 年）內複合年成長率為 9.4%。

慢性疾病的快速成長和人們對個人化醫療日益成長的興趣正在推動生物製藥市場的發展，而轉染技術在其研發和生產中發揮關鍵作用。基因療法，特別是針對遺傳性疾病和癌症的基因療法的快速發展，凸顯了高效病毒載體系統的重要性，從而推動了該領域的需求。持續的研發工作催生了用於轉染試劑的創新化學成分和技術，旨在提高療效並降低細胞毒性。此外，分子和細胞生物學研究的快速發展進一步推動了學術機構、研究實驗室和製藥公司對轉染技術的需求。由於市場競爭依然激烈，各家公司，尤其是在基因治療領域，正致力於創新、產品差異化和合規性。

轉染技術市場促進因素

在轉染技術領域，共轉染是一種將多種核酸同時導入真核細胞的重要技術。此技術可將質體DNA、siRNA和多種miRNA組合起來，促進基因表現和調控。其主要目的是將多個外源基因整合到宿主細胞中，從而推動基因治療和疫苗研發等領域的發展。尤其值得一提的是，該技術利用HEK293等細胞株中的各種質體載體，建構包括慢病毒在內的複雜病毒載體，大大拓展了研究與治療的可能性。

轉染技術市場限制因素

由於各種滅菌方法高成本且操作複雜，轉染技術市場面臨許多限制因素。這些方法通常需要專用設備和專有組件，導致前期投入和後續維護成本都很高。此外，對專業知識的需求也會進一步阻礙其普及，尤其對於預算有限的學術研究人員和小規模生物技術公司而言更是如此。因此，與這些滅菌技術相關的經濟壁壘會限制其在市場上的推廣和廣泛應用，並給那些希望有效利用這些技術的使用者帶來挑戰。

轉染技術市場趨勢

轉染技術市場正經歷一個顯著的趨勢，即採用先進的核酸遞送系統，包括脂質奈米顆粒、聚合物載體和病毒載體。這一趨勢的驅動力在於對更高轉染效率、更精準的細胞標靶化和更低細胞毒性的需求，使得這些技術在基因治療、藥物遞送和基因組編輯等應用領域極具吸引力。隨著生物醫學研究的不斷深入，人們越來越重視開發安全有效的病毒技術。這反映了業界對臨床應用和前沿研究計劃中創新解決方案日益成長的需求的積極回應。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特的分析和影響

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 技術進步
• 監管環境
• 價值鏈分析
• 案例研究分析
• PESTEL 分析
• 總體經濟指標
• 市場吸引力指數

全球轉染技術市場規模（依產品及複合年成長率分類）（2026-2033 年）

• 成套工具
• 裝置

全球轉染技術市場規模（依方法及複合年成長率分類）（2026-2033 年）

• 物理轉染
  • 電穿孔
  • 基因槍轉染/基因槍
  • 顯微注射
  • 其他物理轉染方法
• 基於生化技術的轉染
  • 脂質體
  • 磷酸鈣轉染
  • 陽離子聚合物轉染
  • DEAE-聚葡萄糖轉染
  • 磁輔助轉染
  • 樹狀聚合物介導的轉染
• 基於病毒載體的轉染
• 共轉染

全球轉染技術市場規模（依應用及複合年成長率分類）（2026-2033 年）

• 生物醫學研究
  • 基因和蛋白質表現研究
  • 癌症研究
  • 基因改造模型
• 治療性藥物遞送
  • 生物治療
  • 電免疫療法
  • 化療
• 蛋白質生產
• 基於細胞的微陣列。

全球轉染技術市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 製藥和生物技術公司
• 合約研究組織 (CRO) 和合約研發生產力組織 (CDMO)
• 學術研究機構
• 其他

全球轉染技術市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 西班牙
  • 法國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2021-2023年營收年比比較

主要企業簡介

• Thermo Fisher Scientific Inc.（US）
• Bio-Rad Laboratories, Inc.（US）
• QIAGEN（Netherlands）
• Merck KGaA（Germany）
• Sartorius AG（Polyplus）（Germany）
• Lonza（Switzerland）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Agilent Technologies, Inc.（US）
• MaxCyte（US）
• Revvity（US）
• Takara Bio Inc.（Japan）
• Promega Corporation（US）
• Danaher Corporation（US）
• BOC Sciences（US）
• RJH BIOSCIENCES（Canada）
• Synvolux（Netherlands）
• Altogen Biosciences（US）
• BioIVT（US）
• Incella GmbH（Germany）
• InvivoGen（France）

結論與建議

Transfection Technologies Market size was valued at USD 1.31 Billion in 2024 and is poised to grow from USD 1.44 Billion in 2025 to USD 2.95 Billion by 2033, growing at a CAGR of 9.4% during the forecast period (2026-2033).

The surging prevalence of chronic diseases and the rising interest in personalized medicine are propelling the biopharmaceuticals market forward, with transfection technologies being pivotal in their development and production. The rapid advancements in gene therapy, particularly for genetic disorders and cancer, underline the necessity for effective viral delivery systems, thus amplifying demand in this sector. Continuous R&D endeavors are yielding innovative chemical formulations for transfection reagents and techniques aimed at enhancing efficacy and reducing cytotoxicity. Furthermore, an upsurge in molecular and cell biology research amplifies the need for transfection technologies across academic institutions, research laboratories, and pharmaceutical companies. As the market remains highly competitive, players are focused on innovation, product differentiation, and compliance with regulatory standards, particularly in gene therapy applications.

Top-down and bottom-up approaches were used to estimate and validate the size of the Transfection Technologies market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Transfection Technologies Market Segments Analysis

Global Transfection Technologies Market is segmented by Product, Method, Application, End User and region. Based on Product, the market is segmented into Kits, Equipment. Based on Method, the market is segmented into Physical transfection (Electroporation, Biolistic transfection/ gene guns, Microinjection, Other physical transfection methods), Biochemical-based transfection (Lipofection, Calcium phosphate transfection, Cationic polymer transfection, DEAE-dextran transfection, Magnet-assisted transfection, Dendrimer-mediated transfection), Viral-vector based transfection, Cotransfection. Based on application, the market is segmented into Biomedical research (Gene and protein expression studies, Cancer research, Transgenic models), Therapeutic delivery (Biotherapeutics, Electroimmunotherapy, Electrochemotherapy), Protein production, Cell-based microarrays. Based on end user, the market is segmented into Pharmaceutical and biotechnology companies, CROs and CDMOs, Academic and research institutes, Other. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Transfection Technologies Market

Co-transfection is a crucial technique in the Transfection Technologies market, allowing for the simultaneous introduction of various nucleic acids into eukaryotic cells. This method supports the use of plasmid DNA alongside combinations of siRNA and multiple miRNAs to facilitate gene expression or regulation. The primary aim is to enable the integration of several foreign genes into a host cell, which can lead to advancements in fields such as gene therapy and vaccine development. Notably, this practice is instrumental in generating complex viral constructs, including lentiviruses, through the utilization of diverse plasmid vectors in cell lines like HEK293, thereby enhancing research and therapeutic possibilities.

Restraints in the Transfection Technologies Market

The Transfection Technologies market faces significant restraints owing to the high costs and complexities associated with various sterilization methods. These methods often require specialized equipment and proprietary components, which can lead to substantial up-front expenses and ongoing maintenance fees. Additionally, the necessity for specialized expertise can further hinder accessibility, particularly for academic researchers and small biotech firms operating on tight budgets. As a result, the economic barriers associated with these sterilization technologies may limit their adoption and availability within the market, creating challenges for those who seek to utilize them effectively.

Market Trends of the Transfection Technologies Market

The Transfection Technologies market is experiencing a significant trend towards the enhanced adoption of advanced delivery systems for nucleic acids, including lipid nanoparticles, polymer-based carriers, and viral vectors. This shift is fueled by the need for improved transfection efficiency, precise cell targeting, and minimized cytotoxicity, thus making these technologies highly attractive for applications in gene therapy, drug delivery, and genome editing. As the biomedical research landscape evolves, there is a heightened focus on developing safe and effective viral technologies, reflecting the industry's response to the increasing demand for innovative solutions in clinical settings and advanced research initiatives.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Technological Advancement
• Regulatory Landscape
• Value Chain Analysis
• Case Study Analysis
• PESTEL Analysis
• Macro-Economic Indicators
• Market Attractiveness Index

Global Transfection Technologies Market Size by Product & CAGR (2026-2033)

• Market Overview
• Kits
• Equipment

Global Transfection Technologies Market Size by Method & CAGR (2026-2033)

• Market Overview
• Physical transfection
  • Electroporation
  • Biolistic transfection/ gene guns
  • Microinjection
  • Other physical transfection methods
• Biochemical-based transfection
  • Lipofection
  • Calcium phosphate transfection
  • Cationic polymer transfection
  • DEAE-dextran transfection
  • Magnet-assisted transfection
  • Dendrimer-mediated transfection
• Viral-vector based transfection
• Cotransfection

Global Transfection Technologies Market Size by Application & CAGR (2026-2033)

• Market Overview
• Biomedical research
  • Gene and protein expression studies
  • Cancer research
  • Transgenic models
• Therapeutic delivery
  • Biotherapeutics
  • Electroimmunotherapy
  • Electrochemotherapy
• Protein production
• Cell-based microarrays.

Global Transfection Technologies Market Size by End User & CAGR (2026-2033)

• Market Overview
• Pharmaceutical and biotechnology companies
• CROs and CDMOs
• Academic and research institutes
• Other

Global Transfection Technologies Market Size & CAGR (2026-2033)

• North America, (Product, Method, Application, End User)
  • US
  • Canada
• Europe, (Product, Method, Application, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Product, Method, Application, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Product, Method, Application, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa, (Product, Method, Application, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Thermo Fisher Scientific Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Polyplus) (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MaxCyte (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Revvity (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Promega Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BOC Sciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• RJH BIOSCIENCES (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Synvolux (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Altogen Biosciences (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioIVT (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Incella GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InvivoGen (France)
  • Conclusio Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation